Novartis in global partnership with Amgen

To develop and commercialise pioneering neuroscience treatments Novartis has entered into a global collaboration with Amgen to commercialise and develop pioneering neuroscience treatments. The companies will partner in the development and commercialisation of a BACE inhibitor programme in Alzheimer’s Disease (AD). Novartis’ oral therapy CNP520 will be the lead molecule and further compounds from both company’s pre-clinical BACE inhibitor programmes may be considered as follow-on molecules. The collaboration will also focus on new Amgen drugs in the migraine field, including phase III AMG 334 and phase I AMG 301. For the migraine programme, Novartis will have global co-development rights and commercial rights outside the US, Canada and Japan. “This Novartis collaboration with Amgen highlights our clear commitment to neuroscience and to bring multiple, new targeted therapies to patients living with…


Link to Full Article: Novartis in global partnership with Amgen